Merck's $15 Billion Offer Shakes the Genomics Market

Merck is pursuing a $15 billion bid for Thermo Fisher Scientific, aiming to expand its foothold in biotechnology and genetic research.

Merck's Core Strategy: Supply‑Chain Dissection

The company seeks to solidify ties with pivotal chip suppliers such as TSMC and ASML, secure rare‑earth access, and accelerate scaling of its genomics platforms.

Genomics‑Weighted Stock Turbulence

Following the announcement, genomics‑focused equities experienced a sharp directional shift; some stocks fell while others rallied.

■Merck's bid amount: $15 billion.

■The offer equals 12% of Thermo Fisher's market capitalization.

■Illumina shares dropped 8% after the news.

■CRISPR Therapeutics shares rose 5%.

Dr. Yaman Ege: This move is less a simple takeover battle and more a financial manifestation of the Europe‑US‑China technology and rare‑earth rivalry. Merck’s integration into the chip supply chain could lower the cost of genomic solutions, potentially opening a new market for Nvidia‑type chip makers. Yet, regulatory hurdles and heightened competition may temper the sustainability of the observed stock swings.